Phase I study of docetaxel plus ifosfamide in patients with advanced cancer

Marx, George; Lewis, Craig; Hall, Kirsten Sundby; Levi, John A.; Ackland, Stephen P.

doi:10.1038/sj.bjc.6600542

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 48 patients a response rate of 38% was observed, with a median survival of 8.5 months [24]. A phase I study of docetaxel 75 mg/m 2 day 1 and ifosfamide at increasing doses from 1,500 to 2,750 mg/m 2 as a continuous infusion, on days 1–3 every 3 weeks, was conducted in 31 patients; 3 complete responses and 3 partial responses were seen [26]. …”

Section: New Drug Combinationsmentioning

confidence: 99%

Ifosfamide in Non-Small Cell Lung Cancer

Boni¹,

Zanelli²

2003

Oncology

View full text Add to dashboard Cite

In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of 20–25%. These results are improved when it is used in combination with cisplatin and mitomycin C. Moreover, in recent years, several new drugs like gemcitabine, taxanes and vinorelbine have been identified, and combinations of two or three drugs have been tested in patients with advanced NSCLC. This paper reviews the main studies recently conducted for the treatment of NSCLC, considering the results obtained by ifosfamide alone and in combination. Three-drug regimens including first-generation cytostatic agents achieve a response rate of about 40% and median survival of 10 months. In combinations with new drugs, ifosfamide shows an improvement in response rate (50%) with a median survival of more than 1 year. Open questions in the treatment of NSCLC are whether three-drug are better than two-drug combinations, and whether cisplatin is still required.

show abstract

Section: New Drug Combinationsmentioning

confidence: 99%

Ifosfamide in Non-Small Cell Lung Cancer

Boni¹,

Zanelli²

2003

Oncology

View full text Add to dashboard Cite

show abstract

“…Three CRs and 3 PRs were seen. The recommended dose for future phase II studies is docetaxel 75 mg/m 2 on day 1 and IFO 2,500 mg/m 2 /day continuous infusion on days 1–3 [51]. …”

Section: Novel Combinations With Chemotherapeutic Agentsmentioning

confidence: 99%

Antiblastic Drug Combinations with Ifosfamide: An Update

Fulfaro

Valerio²,

Badalamenti³

et al. 2003

Oncology

View full text Add to dashboard Cite

Ifosfamide is an alkylating agent that is widely used in the treatment of various neoplasms, such as sarcomas, lymphomas, pediatric malignancies, germ cell tumors, lung, breast and ovarian cancer. The clinical toxicity of ifosfamide depends on the dose and administration schedules. The pharmacologic features of this drug enable its combination with other antiblastic agents, such as vinorelbine, gemcitabine, paclitaxel and docetaxel. Moreover, the pharmacologic profile of ifosfamide allows the use of this antiblastic drug in patients who have previously failed many other treatments, and a large percentage of responses has already been obtained. There is some concern about the optimal scheduling of the drug with other novel chemotherapeutics. Clinical trials that include pharmacokinetic and pharmacodynamic studies may be the most efficient way to optimize the therapeutic efficacy of ifosfamide and define the dosing and scheduling.

show abstract